Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Bristol Myers Squibb Company BMY

Healthcare — Drug Manufacturers General
S&P 500 Member Dividend Aristocrat
Indexes indicate stock being part of an index ,
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
2.29
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — 1 — — — 1 1
Insider Ownership
0.10%

Capital & Financial Ratios

Market Cap
128,570.00
Revenue
49,186.00
Net Income
9,274.00
Free Cash Flow
11,440.00
Net Debt
32,053.00
Current Ratio
1.53
Debt/Equity
1.93
P/E ratio
13.89
P/S ratio
2.62
P/B ratio
5.77
Past 5Y EPS Growth
5.14%
This Y EPS Growth
13.08%
Next Y EPS Growth
(5.67%)
Next 5Y EPS Growth
(2.86%)
in millions of $

Dividends

Payout Ratio
0.60
Annual Dividend Rate
2.28
Annual Dividend Yield
5.04%
total individual payouts
2028 ‡‡‡‡‡
2027 ‡‡‡‡‡
2026 2.52
—
—
—
—
2025 2.48
—
—
—
—
2024 2.40
—
—
—
—
2023 2.28
—
—
—
—
2022 2.16
—
—
—
—
2021 1.47
—
—
—
2020 2.29
—
—
—
—
—
2019 1.64
—
—
—
—
2018 1.60
—
—
—
—
2017 1.56
—
—
—
—
2016 1.14
—
—
—
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 12,280.00 10,859.00 10,673.00 11,067.00
Receivables 10,921.00 10,747.00 11,414.00 10,553.00
Inventory 2,662.00 2,557.00 2,690.00 2,737.00
Other 5,907.00 5,617.00 4,613.00 4,222.00
31,770.00 29,780.00 29,390.00 28,579.00
2023 2024 2025 Q'26
Payables 3,259.00 3,602.00 3,575.00 4,158.00
ST’ Debt 3,119.00 2,046.00 2,261.00 1,027.00
Other 15,884.00 18,126.00 17,581.00 13,474.00
22,262.00 23,774.00 23,417.00 18,659.00
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 11,489.00 12,973.00 — —
—
’25 11,201.00 12,269.00 12,222.00 12,502.00
48,194.00
’24 11,865.00 12,201.00 11,892.00 12,342.00
48,300.00
’23 11,337.00 11,226.00 10,966.00 11,477.00
45,006.00
’22 11,648.00 11,887.00 11,218.00 11,406.00
46,159.00
’21 11,073.00 11,703.00 11,624.00 11,985.00
46,385.00
’20 10,781.00 10,129.00 10,540.00 11,068.00
42,518.00
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 1,104.00 3,393.00 — —
—
’25 1,954.00 3,917.00 6,311.00 1,974.00
14,156.00
’24 2,834.00 2,326.00 5,591.00 4,439.00
15,190.00
’23 2,970.00 1,887.00 4,751.00 4,252.00
13,860.00
’22 3,812.00 2,261.00 3,687.00 3,306.00
13,066.00
’21 3,824.00 3,060.00 5,266.00 4,057.00
16,207.00
’20 3,937.00 4,493.00 2,267.00 3,355.00
14,052.00
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 757.00 3,088.00 — —
—
’25 1,694.00 3,556.00 5,991.00 1,604.00
12,845.00
’24 2,550.00 2,064.00 5,267.00 4,061.00
13,942.00
’23 2,692.00 1,628.00 4,409.00 3,922.00
12,651.00
’22 3,559.00 1,989.00 3,440.00 2,960.00
11,948.00
’21 3,651.00 2,850.00 4,996.00 3,737.00
15,234.00
’20 3,751.00 4,362.00 2,114.00 3,072.00
13,299.00
in millions of $

EPS

Mar Jun Sep Dec Year
’26 1.31 1.62 — —
—
’25 1.20 0.64 1.08 0.53
3.46
’24 (5.89) 0.83 0.60 0.04
(4.41)
’23 1.07 0.99 0.93 0.87
3.86
’22 0.59 0.66 0.75 0.95
2.95
’21 0.89 0.47 0.69 1.07
3.12
’20 (0.34) (0.04) 0.82 (4.45)
(3.99)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

2.5
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 60.86 48.25 39.35 42.52 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 81.44 75.18 61.08 63.33 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 34,300 34,100 34,100 32,500 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.35 1.32 1.42 1.48 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 46,159.00 45,006.00 48,300.00 48,194.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 78.04% 76.24% 71.08% 71.08% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7,713.00 8,440.00 (8,379.00) 9,328.00 — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 16.71% 18.75% (17.35%) 19.36% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6,345.00 8,040.00 (8,933.00) 7,055.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10,276.00 9,760.00 9,600.00 4,011.00 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 21.67 21.75 23.83 23.69 ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 2.97 3.88 (4.41) 3.47 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.13 6.70 7.49 6.96 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.52) (0.58) (0.62) (0.64) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.61 6.11 6.88 6.32 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 14.61 14.25 8.08 9.10 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,130.00 2,069.00 2,027.00 2,034.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ 24.25 13.60 0.00 15.59 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.33 2.43 2.37 2.28 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.95 3.70 7.00 5.93 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.99 3.04 3.18 2.99 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 15.40 10.80 11.01 11.22 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13,066.00 13,860.00 15,190.00 14,156.00 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1,118.00) (1,209.00) (1,248.00) (1,311.00) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11,948.00 12,651.00 13,942.00 12,845.00 — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5,383.00 9,508.00 6,006.00 5,973.00 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 39,320.00 39,772.00 49,649.00 45,111.00 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 30,067.00 27,492.00 38,790.00 34,438.00 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 31,118.00 29,485.00 16,388.00 18,506.00 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.14% 8.36% (9.53%) 7.72% — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.88% 9.26% (9.49%) 11.01% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 18.85% 26.48% (39.01%) 40.43% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Bristol Myers Squibb (BMY) exemplifies Big Pharma’s high-stakes evolution, propelled by the transformative $74 billion Celgene acquisition in 2019 that catapulted revenue from $26 billion to over $45 billion annually, fueled by oncology blockbusters like Revlimid. Yet, this growth now confronts patent cliffs—Revlimid’s U.S. exclusivity loss eroded sales, flattening 2025 revenue projections at $48.2 billion and signaling modest declines ahead. Resilient cash cows like Eliquis and Opdivo, paired with operational efficiencies (revenue per employee exceeding $1.4 million), underscore a steadying giant amid volatility from integration costs and one-time charges.

Profitability swings wildly—$9 billion losses in 2020 and 2024 from impairments contrast with robust operating cash flow nearing $16 billion and free cash flow per share at $6.32, funding dividends, buybacks, and a $12-14 billion M&A war chest despite $45 billion debt. Insider activity tilts bearish, highlighted by the CFO’s $2.65 million share sale, tempering optimism. Balance sheet metrics like ROE’s projected 40% rebound in 2025 and compressing EV/FCF at 11x reveal undervaluation, with forward P/E at 12-13x versus peers.

Forward, BMY pivots to innovation via RayzeBio’s radiopharma and Karuna’s KarXT neuroscience approvals, eyeing 5-10% growth by 2028 amid earnings surges to $10 billion net income in 2026. Analyst targets suggest up to 19% upside, positioning this dividend stalwart as a patient investor’s turnaround play—balancing Celgene’s legacy hangover with next-gen promise in a sector yearning for predictability.

Read full commentary →

Bristol Myers Squibb Company (BMY) Latest News

News by impact score

Fine-tune

20 Sep

3 www.fool.com, 8:50 AM
Wall Street analysts are intensifying positive forecasts for Bristol Myers Squibb, pointing to stronger pipeline prospects and potential revenue growth that could lift the company's market position. Rising analyst optimism can lift near-term investor sentiment and share price without altering core operations or long-term strategy.

18 Sep

3 , 3:17 PM
Long-term PsA data for Sotyktu may strengthen Bristol Myers Squibb's market position and growth outlook through expanded indications and competitive gains. Long-term Sotyktu data in PsA can moderately lift revenue prospects and product positioning but remains limited by competition and other pipeline factors.

3 , 12:32 AM
Bristol-Myers Squibb draws fresh market attention amid ongoing pipeline updates and competitive positioning shifts in key therapeutic areas. Developments may moderately influence BMY financial performance and market sentiment without fundamentally altering long-term trajectory.

17 Sep

3 , 6:59 AM
Bristol Myers Squibb presented two-year data on Sotyktu (deucravacitinib) confirming durable efficacy and consistent safety in adults with psoriatic arthritis. Positive long-term Sotyktu data in psoriatic arthritis supports potential regulatory and commercial gains for BMY.

15 Sep

3 , 7:15 AM
Positive Phase 2 myeloma data for Arlo-cel may alter the bull case for Bristol Myers Squibb. Arlo-cel positive Phase 2 data introduces competitive pressure in myeloma that may moderately affect Bristol Myers Squibb positioning.

11 Sep

4 , 11:16 AM
Bristol Myers Squibb secures a win for its cancer therapy that strengthens the company's oncology pipeline. Cancer therapy success directly bolsters Bristol Myers Squibb oncology pipeline and future prospects.

10 Sep

4 , 1:14 PM
Revolution Medicines' breakthrough cancer drug captures additional market share from Bristol Myers Squibb oncology products. Competitor's oncology advance directly erodes BMY market position and revenue outlook.

9 Sep

4 , 5:50 AM
Bristol Myers Squibb issues clinical, regulatory and commercial intelligence report on SOTYKTU projected through 2026. SOTYKTU is a key growth product for Bristol Myers Squibb whose clinical and commercial trajectory directly shapes company revenues and positioning.

3 , 5:34 PM
CAR-T safety concerns are shaking the sector and could allow Bristol-Myers Squibb (BMY) to outperform Novartis (NVS). CAR-T safety issues may shift competitive positioning between Bristol-Myers Squibb and Novartis without fundamentally redefining either company's trajectory.

3 , 11:14 AM
BMY pipeline progress may support portfolio expansion through new drug candidates and development milestones. Pipeline updates can moderately affect long-term revenue and positioning but lack confirmed major launches or approvals.

8 Sep

4 www.biopharmadive.com, 10:41 AM
Roivant shares surge on exceptional clinical results while Bristol Myers Squibb highlights its first-of-its-kind CAR-T therapy. BMY's first-of-its-kind CAR-T therapy marks a major oncology innovation likely to drive significant future growth and market positioning.

4 , 6:59 AM
Bristol Myers Squibb reports positive topline results from its Phase 2 QUINTESSENTIAL trial for arlocabtagene autoleucel, a potential first-in-class GPRC5D-directed CAR T cell therapy. Positive Phase 2 results for a novel CAR T therapy advance Bristol Myers Squibb's oncology pipeline toward potential market approval.

4 Sep

3 , 5:10 AM
Bristol Myers Squibb paused Zola-Cel trials over safety concerns. Trial pause over safety concerns creates a moderate setback for BMY pipeline progress and near-term sentiment.

3 Sep

3 www.trefis.com, 12:07 PM
Merck investors may be prematurely discounting Keytruda's post-patent value, with potential competitive shifts for Bristol Myers Squibb's Opdivo in oncology. Keytruda's future valuation uncertainty could modestly alter immuno-oncology market dynamics and BMY positioning.

3 , 12:31 AM
Bristol Myers Squibb paused a clinical trial, prompting questions over delays and risks to its drug pipeline development and future product flow. Trial pause creates moderate uncertainty around pipeline timelines and may influence near-term development plans without overhauling overall strategy.

2 Sep

3 , 2:30 PM
CYTK's aficamten shows potential to boost hypertrophic cardiomyopathy growth amid ongoing competition with BMY's mavacamten in the HCM market. Potential competitor drug progress may moderately affect BMY positioning in HCM without immediate major shifts.

3 , 11:07 AM
Bristol Myers Squibb shares advance on positive Camzyos data, but the move raises questions over whether further upside remains available or is already reflected in the price. Camzyos data release produces a short-term share price lift for Bristol Myers Squibb without evidence of a fundamental shift in long-term trajectory.

3 www.biopharmadive.com, 8:32 AM
Novartis and Bristol Myers Squibb halted an autoimmune CAR-T study, raising doubts on the therapy approach and its development prospects. Halted study creates uncertainty around autoimmune CAR-T pipeline progress for Bristol Myers.

31 Aug

3 www.biopharmadive.com, 1:38 PM
Novartis and Bristol Myers Squibb paused autoimmune CAR-T trials due to safety concerns. Pausing CAR-T trials for autoimmune use over safety issues may delay BMY pipeline progress in that area.

29 Aug

3 , 11:00 AM
Bristol Myers Squibb presented data up to five years at the ESC Congress 2026 confirming sustained efficacy and safety of Camzyos (mavacamten) for symptomatic obstructive hypertrophic cardiomyopathy. Positive reinforcement of Camzyos long-term data supports moderate gains in market confidence for the cardiovascular franchise.

28 Aug

3 , 10:28 PM
Johnson & Johnson partners with Sail Biomedicines to advance CAR-T therapies and gain competitive edge over Bristol Myers Squibb. JNJ partnership targets CAR-T leadership potentially eroding BMY competitive position in key oncology area.

3 , 5:45 AM
Cytokinetics achieves a first-ever milestone win against Bristol Myers Squibb in their direct competitive rivalry. Rival's first milestone win introduces moderate competitive pressure that may affect BMY positioning in shared markets.

27 Aug

4 , 8:11 PM
Bristol-Myers Squibb receives new FDA approval for an oncology treatment, creating an additional growth catalyst in its core cancer drug portfolio. New FDA oncology approval directly expands Bristol-Myers Squibb product pipeline and revenue potential in a key therapeutic area.

4 , 10:32 AM
Bristol Myers Squibb faces major patent expirations on key drugs while Camzyos growth is positioned to offset resulting revenue declines and support future performance. Camzyos uptake versus patent cliffs will materially shape BMY revenue trajectory and investor outlook over coming years.

3 , 8:36 PM
Bristol-Myers Squibb exits Cellares partnership, raising doubts over growth outlook for its Breyanzi cell therapy product. Cellares exit introduces uncertainty around Breyanzi expansion and related revenue prospects.

26 Aug

4 , 9:20 AM
Multibillion-dollar mRNA cancer market emerges with focus on lung cancer opportunity involving Bristol Myers Squibb. mRNA cancer market formation around lung cancer creates major strategic opportunity for BMY.

4 , 5:08 AM
Bristol Myers Squibb secured ZENBEXUS approval amid patent actions that introduce new revenue potential alongside legal and competitive risks to its drug portfolio and market position. ZENBEXUS approval adds a major new product while patent actions create litigation and competitive exposure that can shift BMY revenues and strategy.

3 , 10:13 PM
ZENBEXUS secures first-in-class CELMoD approval based on MRD-negative CR, potentially shifting Bristol Myers Squibb competitive position and market narrative. Competitor CELMoD approval introduces moderate pressure on BMY product positioning without immediate fundamental trajectory change.

24 Aug

3 www.trefis.com, 2:36 PM
Exelixis owners are increasing their stake in Bristol Myers Squibb during its ongoing transition, potentially reshaping ownership structure and strategic priorities. Shifts in Exelixis ownership may moderately influence BMY strategic direction and investor sentiment amid transition.

21 Aug

4 , 3:28 PM
Bristol Myers Squibb commits $2.3 billion to Texas operations while Eli Lilly secures advantages in the UK. BMY's $2.3 billion Texas investment marks a major capital expansion with potential to strengthen manufacturing capacity and future performance.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us